Competition in Semaglutide API: From “Who Expands Fastest” to “Who Builds Strength” (Analysis of China’s Three Major Echelons)
The competition in semaglutide active pharmaceutical ingredient (API) has shifted from “who expands fastest” to “who builds strength”. The differentiation of the three major echelons marks the semaglutide industry’s entry into a new stage driven by capabilities. In the future, only enterprises with scale, technology, cost control and industrial chain synergy can gain a foothold […]

